The continuous infusion of recombinant activated factor VIIa (rFVIIa) in patients with factor VIII inhibitors activates the coagulation and fibrinolytic systems without clinical complications - Baudo, F; Redaelli, R; Caimi, TM (Thromb Res, 2000)
et al.